Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sydney Dowell

Nurse Practitioner Louisville, KY Nurse Practitioner

NPI 1144243379 CMS profile 10533261

8442 Dixie Hwy, Louisville, KY 40258

Open in the dashboard

General payments

$5,447

318 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sydney Dowell of Louisville, KY is reported in the CMS Open Payments database as having received $5,447 across 318 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $847 50
2024 General $1,063 56
2023 General $814 51
2022 General $977 57
2021 General $1,746 104

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sydney Dowell
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sydney Dowell were reported at $847. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sydney Dowell Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,746 $135 $40–$426 $132
2022 $977 $152 $48–$470 $149
2023 $814 $166 $54–$529 $160
2024 $1,063 $173 $55–$556 $164
2025 $847 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,302 90 payments
  2. Pfizer Inc. $576 43 payments
  3. Amgen Inc. $440 31 payments
  4. Novo Nordisk Inc $277 10 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $256 18 payments
  6. Biohaven Pharmaceuticals, Inc. $229 7 payments
  7. Medtronic, Inc. $223 9 payments
  8. GlaxoSmithKline, LLC. $210 13 payments
  9. Esperion Therapeutics, Inc. $208 15 payments
  10. Vanda Pharmaceuticals Inc. $200 9 payments
  11. Other $1,525 73 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,447 318 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $650 45 payments
  2. Repatha $367 26 payments
  3. NURTEC ODT Pain $339 26 payments
  4. NURTEC ODT Primary Care $314 11 payments
  5. UBRELVY $242 15 payments
  6. Otezla $236 17 payments
  7. ZAVZPRET $231 14 payments
  8. VRAYLAR Neuroscience $221 14 payments
  9. TRELEGY ELLIPTA $210 13 payments
  10. NEXLETOL $208 15 payments
  11. Other $4,022 231 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 112 drugs

Part D claims

5,585

Median for Nurse Practitioner: 389

Drug cost

$561,179

Median for Nurse Practitioner: $21,885

Branded share of claims

22.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 115 $142,335
Rybelsus Semaglutide Brand 55 $58,311
Eliquis Apixaban Brand 47 $51,179
Januvia Sitagliptin Phosphate Brand 33 $38,882
Mounjaro Tirzepatide Brand 30 $33,540
Nurtec Odt Rimegepant Sulfate Brand 22 $25,713
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 23 $21,089
Linzess Linaclotide Brand 31 $20,659
Farxiga Dapagliflozin Propanediol Brand 17 $19,150
Vascepa Icosapent Ethyl Brand 27 $13,646

The 10 drugs with the highest cost, of 112 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$18,717

Of which drugs: $134

Medicare patients

127

Average age 69

Services billed

798

87 women, 40 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Depression 44%
Diabetes 39%
Chronic kidney disease 32%
Ischemic heart disease 21%
COPD 20%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 11 375 $87

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $197
$197 — —
Auvelity
  • Axsome Therapeutics, Inc. $106
$106 — —
NURTEC ODT
  • PFIZER INC. $74
$74 22 —
Korlym
  • Corcept Therapeutics $66
$66 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

318 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record